Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md. , June 05, 2025...
NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTIONS
UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND IN RE EMERGENT BIOSOLUTIONS INC. , STOCKHOLDER DERIVATIVE LITIGATION Master Case No.: 8:21-cv-01595-DLB ...
Summary Notice of Pendency and Proposed Settlement of Derivative Actions
YOU ARE HEREBY NOTIFIED that this Summary Notice relates to a proposed settlement (“Settlement”) of the following derivative actions: In re Emergent BioSolutions Inc. Stockholder Deriv. Litig.,...
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md. , May 14, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following...
Emergent BioSolutions Reports First Quarter 2025 Financial Results
First Quarter 2025 Total Revenues of $222.2 million , decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million , increase of 656% versus prior year First Quarter 2025 Gross...
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario WINNIPEG, Manitoba , May 01, 2025 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE: EBS)...
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
GAITHERSBURG, Md. , April 22, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
GAITHERSBURG, Md. , March 20, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md. , March 20, 2025...
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GAITHERSBURG, Md. , March 19, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore -Bayview drug substance manufacturing...
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
GAITHERSBURG, Md. , March 18, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted...
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN ® Nasal Spray and provide trainings on how to administer the...